- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00396383
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
Treatment With AMD3100 in Multiple Myeloma Patients to Mobilize Peripheral Blood Progenitor Cells For Collection and for Transplantation
Studie Overzicht
Gedetailleerde beschrijving
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and well tolerated in multiple myeloma (MM) patients. In addition, this study determines if 240 µg/kg plerixafor alone can be used to mobilize peripheral blood progenitor cells (PBPCs) for transplantation in MM patients. The minimum number of CD34+ cells to collect is 2*10^6 CD34+ cells/kg and the target is ≧4*10^6 CD34+ cells/kg. Success of transplant engraftment will be measured by the number of days to polymorphonuclear leukocytes (PMN) and platelet (PLT) engraftment. Durability of engraftment will be assessed for a minimum of one year.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Thomas Jefferson University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of multiple myeloma (MM)
- Eligible for autologous transplantation
- Patients in first or second partial remission (PR) or complete remission (CR)
- Patients who have received ≦2000 rads of prior radiation therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Recovered from all acute toxic effects of prior chemotherapy
- White blood cells (WBC) >3.0*10^9/l
- Absolute polymorphonuclear leucocyte (PMN) count >1.5*10^9/l
- Platelet (PLT) count > 150*10^9/l
- Serum creatinine ≦2.2 mg/dl
- Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin <2 x upper limit of normal (ULN)
- Negative for HIV
- Signed informed consent
- Patients of childbearing potential agree to use an approved form of contraception
Exclusion Criteria:
- Patient received 2 or more alkylating agents, such as VBMCP (a combination of Vincristine, BCNU (Bis-Chloronitrosourea), Melphalan, Cyclophosphamide, and Prednisone)
- Patient received a total dose of ≧200 mg of prior melphalan
- A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications
- Patient has failed previous collections or collection attempts
- A residual acute medical condition resulting from prior chemotherapy
- Brain metastases or carcinomatous meningitis
- Acute infection
- Fever (temperature >38 °C / 100.4 °F)
- Hypercalcemia (>1mg/dl above ULN)
- Positive pregnancy test in female patients
- Lactating females
- Patients of childbearing potential unwilling to implement adequate birth control
- Patients whose actual body weight exceeds 175% of their ideal body weight
- History of ventricular arrhythmias
- Patient received thalidomide within 10 days prior to receiving the first dose of plerixafor
- Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Participants with Multiple Myeloma (MM)
Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
|
Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later.
Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4*10^6 CD34+ cells/kg body weight had been collected.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg
Tijdsspanne: Day 1 up to day 4
|
Number of participants achieving a target of ≥ 4*10^6 CD34+ cells/kg during apheresis for up to 4 consecutive days.
Apheresis was performed six hours following treatment with plerixafor 240 µg/kg (alone).
Target was calculated as the sum of all daily values collected from central laboratory data over up to 4 apheresis days.
|
Day 1 up to day 4
|
Participant Counts of Summarized Adverse Events (AE) During Treatment
Tijdsspanne: 1 month
|
Participant counts of summarized adverse events (AEs) which occurred from the first dose of plerixafor up to the day prior to chemotherapy/ablative treatment.
Events were graded according to World Health Organization criteria: Mild (awareness of sign or symptom, but easily tolerated), Moderate (discomfort enough to cause interference with usual activity), Severe (incapacitating with inability to work or do usual activity).
|
1 month
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment
Tijdsspanne: Approximately 2 months
|
Polymorphonuclear cell (PMN) engraftment was defined as a PMN count ≥ 0.5*10^9/L for 3 consecutive days or ≥ 1*10^9/L for 1 day.
Days to engraftment corresponded to the first day that the criteria were met after transplantation.
|
Approximately 2 months
|
Number of Transplantations That Achieved Platelet (PLT) Engraftment Grouped by Days to Engraftment
Tijdsspanne: Approximately 2 months
|
Platelet (PLT) engraftment was defined as a PLT count of ≥ 20*10^9/L for 7 days without transfusion.
Days to engraftment corresponded to the first day that the criteria were met after transplantation.
|
Approximately 2 months
|
Number of Participants With a Durable Graft at 12 Months Post Transplantation
Tijdsspanne: Approximately month 13
|
Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation.
|
Approximately month 13
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Flomenberg N, Comenzo R, Badel K, Calandra G. Single agent AMD3100 mobilization of peripheral blood progenitor cells for autologous transplantation in patients with multiple myeloma (MM) [abstract]. Blood. Nov 16 2006;108(11 Pt 1):965a.
- Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):695-700. doi: 10.1016/j.bbmt.2009.12.538. Epub 2010 Jan 11.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Vaatziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Hematologische ziekten
- Hemorragische aandoeningen
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Multipel myeloom
- Neoplasmata, plasmacel
- Anti-infectieuze middelen
- Antivirale middelen
- Anti-hiv-middelen
- Antiretrovirale middelen
- Plerixafor
Andere studie-ID-nummers
- AMD3100-2108
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Multipel myeloom
-
University of ArkansasVoltooidMEERDERE MYELOMAVerenigde Staten
-
PETHEMA FoundationGlaxoSmithKlineWervingTERUGVALLEN EN/OF REFRACTAIRE MEERDERE MYELOMASpanje
-
Mario BoccadoroActief, niet wervend
-
Beth Israel Deaconess Medical CenterAmgenVoltooidAML | MDS | CLL | ALLE | CML Chronic Phase, Accelerated Phase, or Blast Crisis | RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA | APLASTIC ANEMIA | MEERDERE MYELOMA | MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Klinische onderzoeken op plerixafor
-
Stephen CoubanGenzyme, a Sanofi CompanyVoltooidKwaadaardig lymfoom, stamceltypeCanada
-
National Heart, Lung, and Blood Institute (NHLBI)Voltooid
-
Kyowa Kirin Co., Ltd.VoltooidMultipel myeloom en kwaadaardig lymfoomJapan
-
Genzyme, a Sanofi CompanyVoltooidNierfunctiestoornisVerenigde Staten
-
University of WashingtonVoltooid
-
University Hospital, Clermont-FerrandVoltooidKinderen Kanker, Vaste TumorFrankrijk
-
National Institute of Allergy and Infectious Diseases...Lombardi Comprehensive Cancer CenterBeëindigdKankerVerenigde Staten
-
SanofiVoltooidAutologe hematopoëtische stamceltransplantatieChina
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaVoltooidAcute myeloïde leukemieCanada